{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:39:51Z","timestamp":1785173991932,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41375-025-02695-3","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T07:00:17Z","timestamp":1752649217000},"page":"2163-2173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization"],"prefix":"10.1038","volume":"39","author":[{"given":"Eric J.","family":"Vick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-3564","authenticated-orcid":false,"given":"Aishlin","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4671-962X","authenticated-orcid":false,"given":"Kwangmin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7859-7252","authenticated-orcid":false,"given":"Courtnee A.","family":"Clough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2744-1864","authenticated-orcid":false,"given":"Ashley E.","family":"Culver-Cochran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Hueneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-5277","authenticated-orcid":false,"given":"Lyndsey C.","family":"Bolanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ceribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carleen","family":"Klumpp-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5316-3351","authenticated-orcid":false,"given":"Kenneth D.","family":"Greis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9001","authenticated-orcid":false,"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5771-7462","authenticated-orcid":false,"given":"Daniel T.","family":"Starczynowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2695_CR1","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1182\/blood.2021014418","volume":"139","author":"LD Weeks","year":"2022","unstructured":"Weeks LD, Marinac CR, Redd R, Abel G, Lin A, Agrawal M, et al. Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2022;139:1246\u201350.","journal-title":"Blood"},{"key":"2695_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107565","volume":"145","author":"A Desai","year":"2024","unstructured":"Desai A, Samara Y, Yang D, Ball B, Braun A, Koller P, et al. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2024;145:107565.","journal-title":"Leuk Res"},{"key":"2695_CR3","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.2217\/fon-2022-0334","volume":"18","author":"V Kota","year":"2022","unstructured":"Kota V, Ogbonnaya A, Farrelly E, Schroader BK, Raju A, Kristo F, et al. Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes. Future Oncol. 2022;18:4017\u201329.","journal-title":"Future Oncol"},{"key":"2695_CR4","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1182\/blood-2011-12-399683","volume":"120","author":"B Will","year":"2012","unstructured":"Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012;120:2076\u201386.","journal-title":"Blood"},{"key":"2695_CR5","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/leu.2012.312","volume":"27","author":"C Craddock","year":"2013","unstructured":"Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, et al. Azacitidine fails to eradicate leukemic stem\/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia. 2013;27:1028\u201336.","journal-title":"Leukemia"},{"key":"2695_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189\u201399.","journal-title":"N Engl J Med"},{"key":"2695_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.exphem.2015.05.016","volume":"43","author":"ME Varney","year":"2015","unstructured":"Varney ME, Melgar K, Niederkorn M, Smith M, Barreyro L, Starczynowski DT. Deconstructing innate immune signaling in myelodysplastic syndromes. Exp Hematol. 2015;43:587\u201398.","journal-title":"Exp Hematol"},{"key":"2695_CR8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","volume":"132","author":"L Barreyro","year":"2018","unstructured":"Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018;132:1553\u201360.","journal-title":"Blood"},{"key":"2695_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8828","volume":"11","author":"K Melgar","year":"2019","unstructured":"Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Sci Transl Med. 2019;11:eaaw8828.","journal-title":"Sci Transl Med"},{"key":"2695_CR10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201544","volume":"218","author":"JJ Trowbridge","year":"2021","unstructured":"Trowbridge JJ, Starczynowski DT. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J Exp Med. 2021;218:e20201544.","journal-title":"J Exp Med"},{"key":"2695_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-023-00422-1","volume":"12","author":"CTR Vegivinti","year":"2023","unstructured":"Vegivinti CTR, Keesari PR, Veeraballi S, Martins Maia CMP, Mehta AK, Lavu RR, et al. Role of innate immunological\/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review. Exp Hematol Oncol. 2023;12:60.","journal-title":"Exp Hematol Oncol"},{"key":"2695_CR12","doi-asserted-by":"crossref","unstructured":"Pellagatti A, Boultwood J. Hyperactivation of NF-\u03baB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches. Adv Biol Regul 2025;95:101055.","DOI":"10.1016\/j.jbior.2024.101055"},{"key":"2695_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","volume":"38","author":"A Perzolli","year":"2024","unstructured":"Perzolli A, Koedijk JB, Zwaan CM, Heidenreich O. Targeting the innate immune system in pediatric and adult AML. Leukemia. 2024;38:1191\u2013201.","journal-title":"Leukemia"},{"key":"2695_CR14","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1182\/blood.2023022804","volume":"143","author":"ABA Laranjeira","year":"2024","unstructured":"Laranjeira ABA, Kong T, Snyder SC, Fulbright MC, Fisher DAC, Starczynowski DT, et al. In vivo ablation of NF-kappaB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood. 2024;143:2414\u201324.","journal-title":"Blood"},{"key":"2695_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","volume":"21","author":"MA Smith","year":"2019","unstructured":"Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol. 2019;21:640\u201350.","journal-title":"Nat Cell Biol"},{"key":"2695_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","volume":"29","author":"J Bennett","year":"2022","unstructured":"Bennett J, Starczynowski DT. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Curr Opin Hematol. 2022;29:8\u201319.","journal-title":"Curr Opin Hematol"},{"key":"2695_CR17","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78136","volume":"11","author":"GS Choudhary","year":"2022","unstructured":"Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, et al. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. Elife. 2022;11:e78136.","journal-title":"Elife"},{"key":"2695_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood.2022018718","volume":"142","author":"J Bennett","year":"2023","unstructured":"Bennett J, Ishikawa C, Agarwal P, Yeung J, Sampson A, Uible E, et al. Paralog-specific signaling by IRAK1\/4 maintains MyD88-independent functions in MDS\/AML. Blood. 2023;142:989\u20131007.","journal-title":"Blood"},{"key":"2695_CR19","doi-asserted-by":"crossref","unstructured":"Venkatasubramanian M, Schwartz L, Ramachandra N, Bennett J, Subramanian KR, Chen X, et al. Broad de-regulated U2AF1 splicing is prognostic and augments leukemic transformation via protein arginine methyltransferase activation. bioRxiv 2024.2002.2004.578798.","DOI":"10.1101\/2024.02.04.578798"},{"key":"2695_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1239082","volume":"14","author":"RD Parrondo","year":"2023","unstructured":"Parrondo RD, Iqbal M, Von Roemeling R, Von Roemeling C, Tun HW. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Front Immunol. 2023;14:1239082.","journal-title":"Front Immunol"},{"key":"2695_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105505","volume":"119","author":"S Lier","year":"2022","unstructured":"Lier S, Sellmer A, Orben F, Heinzlmeir S, Krauss L, Schneeweis C, et al. A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. Bioorg Chem. 2022;119:105505.","journal-title":"Bioorg Chem"},{"key":"2695_CR22","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/sj.onc.1202199","volume":"17","author":"L Soucek","year":"1998","unstructured":"Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998;17:2463\u201372.","journal-title":"Oncogene"},{"key":"2695_CR23","volume":"13","author":"Y Miao","year":"2023","unstructured":"Miao Y, Du Q, Zhang HG, Yuan Y, Zuo Y, Zheng H. Cycloheximide (CHX) Chase Assay to Examine Protein Half-life. Bio Protoc. 2023;13:e4690.","journal-title":"Bio Protoc"},{"key":"2695_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/1947601910377495","volume":"1","author":"MD Delgado","year":"2010","unstructured":"Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer. 2010;1:605\u201316.","journal-title":"Genes Cancer"},{"key":"2695_CR25","doi-asserted-by":"publisher","first-page":"G266","DOI":"10.1152\/ajpgi.90583.2008","volume":"296","author":"T Eismann","year":"2009","unstructured":"Eismann T, Huber N, Shin T, Kuboki S, Galloway E, Wyder M, et al. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice. Am J Physiol Gastrointest Liver Physiol. 2009;296:G266\u2013274.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2695_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coi.2003.11.013","volume":"16","author":"A Puel","year":"2004","unstructured":"Puel A, Picard C, Ku CL, Smahi A, Casanova JL. Inherited disorders of NF-kappaB-mediated immunity in man. Curr Opin Immunol. 2004;16:34\u201341.","journal-title":"Curr Opin Immunol"},{"key":"2695_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.celrep.2012.02.009","volume":"1","author":"M Etzrodt","year":"2012","unstructured":"Etzrodt M, Cortez-Retamozo V, Newton A, Zhao J, Ng A, Wildgruber M, et al. Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep. 2012;1:317\u201324.","journal-title":"Cell Rep"},{"key":"2695_CR28","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-21-0947","volume":"21","author":"J Fernandez-Rodriguez","year":"2022","unstructured":"Fernandez-Rodriguez J, Creus-Bachiller E, Zhang X, Martinez-Iniesta M, Ortega-Bertran S, Guha R, et al. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. Mol Cancer Ther. 2022;21:1246\u201358.","journal-title":"Mol Cancer Ther"},{"key":"2695_CR29","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ccell.2024.05.026","volume":"42","author":"A Bolomsky","year":"2024","unstructured":"Bolomsky A, Ceribelli M, Scheich S, Rinaldi K, Huang DW, Chakraborty P, et al. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer Cell. 2024;42:1185\u20131201.e1114.","journal-title":"Cancer Cell"},{"key":"2695_CR30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2024.04.007","volume":"42","author":"J Choi","year":"2024","unstructured":"Choi J, Ceribelli M, Phelan JD, Haupl B, Huang DW, Wright GW, et al. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer Cell. 2024;42:833\u2013849.e812.","journal-title":"Cancer Cell"},{"key":"2695_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu C-C, Miller K, et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature. 2016;535:252\u20137.","journal-title":"Nature"},{"key":"2695_CR32","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1021\/acsmedchemlett.0c00255","volume":"11","author":"VR Gummadi","year":"2020","unstructured":"Gummadi VR, Boruah A, Ainan BR, Vare BR, Manda S, Gondle HP, et al. Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies. ACS Med Chem Lett. 2020;11:2374\u201381.","journal-title":"ACS Med Chem Lett"},{"key":"2695_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinf. 2013;14:128.","journal-title":"BMC Bioinf"},{"key":"2695_CR34","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","volume":"64","author":"JD Hansen","year":"2021","unstructured":"Hansen JD, Correa M, Alexander M, Nagy M, Huang D, Sapienza J, et al. CC-90009: A Cereblon E3 Ligase Modulating Drug that promotes selective degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2021;64:1835\u201343.","journal-title":"J Med Chem"},{"key":"2695_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2022017813","volume":"142","author":"Y Chang","year":"2023","unstructured":"Chang Y, Keramatnia F, Ghate PS, Nishiguchi G, Gao Q, Iacobucci I, et al. The orally bioavailable GSPT1\/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia. Blood. 2023;142:629\u201342.","journal-title":"Blood"},{"key":"2695_CR36","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1158\/1535-7163.MCT-17-1209","volume":"17","author":"A Local","year":"2018","unstructured":"Local A, Zhang H, Benbatoul KD, Folger P, Sheng X, Tsai C-Y, et al. APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells. Mol Cancer Therapeut. 2018;17:1177\u201386.","journal-title":"Mol Cancer Therapeut"},{"key":"2695_CR37","doi-asserted-by":"crossref","unstructured":"Sellar RS, Sperling AS, S\u0142abicki M, Gasser JA, McConkey ME, Donovan KA, et al. Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells. J Clin Invest. 2022;132:e153514.","DOI":"10.1172\/JCI153514"},{"key":"2695_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"2695_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","volume":"33","author":"P Tardi","year":"2009","unstructured":"Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33:129\u201339.","journal-title":"Leuk Res"},{"key":"2695_CR40","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.apsb.2021.10.021","volume":"12","author":"X Gao","year":"2022","unstructured":"Gao X, You J, Gong Y, Yuan M, Zhu H, Fang L, et al. WSB1 regulates c-Myc expression through \u03b2-catenin signaling and forms a feedforward circuit. Acta Pharm Sin B. 2022;12:1225\u201339.","journal-title":"Acta Pharm Sin B"},{"key":"2695_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/1947601911416357","volume":"2","author":"B Salvatori","year":"2011","unstructured":"Salvatori B, Iosue I, Djodji Damas N, Mangiavacchi A, Chiaretti S, Messina M, et al. Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. Genes Cancer. 2011;2:585\u201392.","journal-title":"Genes Cancer"},{"key":"2695_CR42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.stem.2021.12.007","volume":"29","author":"T Muto","year":"2022","unstructured":"Muto T, Guillamot M, Yeung J, Fang J, Bennett J, Nadorp B, et al. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022;29:298\u2013314.e299.","journal-title":"Cell Stem Cell"},{"key":"2695_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01308-8","volume":"20","author":"B Moser","year":"2021","unstructured":"Moser B, Hochreiter B, Bas\u00edlio J, Gleitsmann V, Panhuber A, Pardo-Garcia A, et al. The inflammatory kinase IKK\u03b1 phosphorylates and stabilizes c-Myc and enhances its activity. Mol Cancer. 2021;20:16.","journal-title":"Mol Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02695-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02695-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02695-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:37:21Z","timestamp":1757245041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02695-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2695"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02695-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DTS serves on the scientific advisory board at Kurome Therapeutics and is a consultant for and\/or received funding from Kurome Therapeutics. DTS has equity in Kurome Therapeutics. The other authors declare no relevant competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods described in this manuscript were performed in accordance with the relevant guidelines and regulations. The animal experiments in this study were performed in compliance with Cincinnati Children\u2019s Institutional Animal Care and Use Committee (IACUC) under the following protocol (2022-0054). Patient samples were obtained with written informed consent and approval of the institutional review board of Cincinnati Children\u2019s Hospital Medical Center and University of Cincinnati, or from the Eastern Cooperative Oncology Group (ECOG). These samples had been obtained within the framework of routine diagnostic BM aspirations after written informed consent in accordance with the Declaration of Helsinki. De-identified leukemic cells were obtained following consent under the IRB approved Study ID #2008-0021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The RNA sequencing data from this study are available on GEO (GSE298391). Cell lines used in these studies are publicly available through commercial sources or may be made available from the authors upon written request and material transfer agreement approval. The authors are also glad to share guidance regarding protocols and assays used in these studies upon written request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data-sharing statement"}}]}}